Kraft AS - Search Results

1

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.

Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Beldner MA, et al. Among authors: kraft as. BMC Cancer. 2007 Dec 20;7:231. doi: 10.1186/1471-2407-7-231. BMC Cancer. 2007. PMID: 18096059 Free PMC article. Clinical Trial.

2

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK. Maki RG, et al. Among authors: kraft as. Cancer. 2005 Apr 1;103(7):1431-8. doi: 10.1002/cncr.20968. Cancer. 2005. PMID: 15739208 Free article. Clinical Trial.

3

Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.

Sui M, Xiong X, Kraft AS, Fan W. Sui M, et al. Among authors: kraft as. Cancer Biol Ther. 2006 Aug;5(8):1015-21. doi: 10.4161/cbt.5.8.2909. Epub 2006 Aug 18. Cancer Biol Ther. 2006. PMID: 16855376

4

Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy.

Xiong X, Sui M, Fan W, Kraft AS. Xiong X, et al. Among authors: kraft as. Cancer Biol Ther. 2007 Jul;6(7):1067-73. doi: 10.4161/cbt.6.7.4323. Cancer Biol Ther. 2007. PMID: 17568189

5

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.

Skorupa A, Beldner M, Kraft A, Montero AJ. Skorupa A, et al. Cancer Biol Ther. 2007 Jul;6(7):1015-7. doi: 10.4161/cbt.6.7.4338. Cancer Biol Ther. 2007. PMID: 17611408

6

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.

Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Hayslip J, et al. BMC Cancer. 2007 Dec 3;7:221. doi: 10.1186/1471-2407-7-221. BMC Cancer. 2007. PMID: 18053191 Free PMC article. Clinical Trial.

7

Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.

Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Kraft AS, et al. Cancer Biol Ther. 2011 Jul 15;12(2):119-24. doi: 10.4161/cbt.12.2.15723. Epub 2011 Jul 15. Cancer Biol Ther. 2011. PMID: 21532336 Clinical Trial.

8

Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.

Marshall DT, Ramey S, Golshayan AR, Keane TE, Kraft AS, Chaudhary U. Marshall DT, et al. Among authors: kraft as. Clin Genitourin Cancer. 2014 Apr;12(2):80-6. doi: 10.1016/j.clgc.2013.11.019. Epub 2013 Nov 13. Clin Genitourin Cancer. 2014. PMID: 24378335 Clinical Trial.

9

A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.

Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. Somaiah N, et al. Among authors: kraft as. Cancer. 2021 Mar 15;127(6):894-904. doi: 10.1002/cncr.33216. Epub 2020 Nov 24. Cancer. 2021. PMID: 33231866 Free article. Clinical Trial.

10

The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.

Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. Nikrad M, et al. Among authors: kraft as. Mol Cancer Ther. 2005 Mar;4(3):443-9. doi: 10.1158/1535-7163.MCT-04-0260. Mol Cancer Ther. 2005. PMID: 15767553

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

183 results

Search Page